Streetbeat News

DOMA

Doma Holdings Inc.

https://www.doma.com

Industry

Real Estate - Services

Doma Holdings Inc. originates, underwrites, and provides title, escrow, and settlement services to homeowners, lenders, title agents, and real estate professionals. It operates through two segments, Distribution and Underwriting. The company also engages in title insurance underwriting business, including policies referred through its direct agents and third-party agents' channels; and provides services in the areas of purchase and refinance transactions in the residential real estate market. It operates its third-party title insurance agency business under the North American Title Company brand. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Open

6.04

Mkt cap

89M

Volume

587K

High

6.29

P/E Ratio

-1.09

52-wk high

6.29

Low

6.04

Div yield

N/A

52-wk low

3.90

Doma Holdings (NYSE:DOMA) reported Q2 EPS of $(1.46), missing the $(1.43) estimate, and sales of $77.65M, missing the $83.95M estimate. Despite the misses, EPS improved by 27.36% YoY, while sales decreased by 4.47% YoY.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:53 pm

Doma Title Insurance has partnered with Intellicheck to combat real estate fraud by offering a free identity validation tool to agents and attorneys to prevent seller impersonation.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:23 pm

JMP Securities has downgraded Doma Holdings (NYSE:DOMA) from Market Outperform to Market Perform, as per analyst Matthew Carletti.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 9:44 am

Doma Holdings reported Q1 EPS of $(1.50), surpassing the $(1.56) estimate, but its sales of $66.00M fell short of the expected $72.56M. This represents a 53.85% improvement in EPS and an 11.25% decrease in sales year-over-year.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 9:28 pm

JMP Securities analyst Matthew Carletti reiterates a Market Outperform rating on Doma Holdings (NYSE:DOMA) and maintains a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 3:36 pm

Citigroup analyst Tom White has maintained a Neutral rating on Doma Holdings (NYSE:DOMA) and increased the price target from $6 to $6.29.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 7:53 pm

U.S. stocks closed mostly lower with the Dow Jones falling over 200 points despite an improvement in the CNN Money Fear and Greed index, which remained in the 'Greed' zone. Inflation rates and personal spending rose, while U.S. construction spending fell. Torrid Holdings and Doma Holdings saw significant movements with Doma entering a merger to go private. Most S&P 500 sectors closed lower except for communication services and energy. Investors await earnings from Cal-Maine Foods, Dave & Buster's, and Paychex.

Portfolio Pulse from Avi Kapoor

April 02, 2024 | 8:19 am

U.S. stocks traded lower with the S&P 500, Dow, and NASDAQ all seeing declines. CXApp Inc. shares surged 145% after announcing a partnership with Google Cloud. Sunshine Biopharma and Doma Holdings also saw significant gains, while Nuvve Holding, AEON Biopharma, and Disc Medicine experienced sharp declines. Torrid Holdings reported strong Q4 results. In commodities, gold and oil prices increased.

Portfolio Pulse from Avi Kapoor

April 01, 2024 | 7:02 pm

Nuvve Holding Corp. shares plummeted by approximately 30% after reporting Q4 financial results significantly below market expectations. Other stocks experienced notable movements, with Vast Renewables and CXApp Inc. leading the gainers, while Eiger BioPharmaceuticals and Andretti Acquisition Corp. were among the biggest losers.

Portfolio Pulse from Avi Kapoor

April 01, 2024 | 6:31 pm

U.S. stocks traded lower with the Dow Jones falling over 300 points. Oxford Industries shares fell more than 4% after reporting downbeat Q4 results and weak Q1 guidance. CXApp Inc. shares surged 143% following a partnership announcement with Google Cloud. Sunshine Biopharma and Doma Holdings also saw significant gains, while Nuvve Holding Corp., AEON Biopharma, and Disc Medicine experienced notable declines.

Portfolio Pulse from Avi Kapoor

April 01, 2024 | 5:47 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.